Skip to content

Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure

Michael R. Bristow, Leslie A. Saxon, JOHN P. BOEHMER, David A. Kass, Teresa De Marco, Peter E. Carson, Lorenzo A. DiCarlo, David L. DeMets, Bill G. White, Dale W. DeVries, Arthur Michael Feldman

New England Journal of Medicine · 2004 · 5,802 citations

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Bristow, M. R., Saxon, L. A., BOEHMER, J. P., Krueger, S., Kass, D. A., Marco, T. D., Carson, P. E., DiCarlo, L. A., DeMets, D. L., White, B. G., DeVries, D. W., & Feldman, A. M. (2004). Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New England Journal of Medicine, 350(21), 2140–2150. https://doi.org/10.1056/nejmoa032423

In text: (Bristow et al., 2004)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: We tested the hypothesis that prophylactic cardiac-resynchronization therapy in the form of biventricular stimulation with a pacemaker with or without a defibrillator would reduce the risk of death and hospitalization among patients with advanced chronic heart failure and intraventricular conduction delays. METHODS: A total of 1520 patients who had advanced heart failure (New York Heart Association class III or IV) due to ischemic or nonischemic cardiomyopathies and a QRS interval of at least 120 msec were randomly assigned in a 1:2:2 ratio to receive optimal pharmacologic therapy (diuretics, angiotensin-converting-enzyme inhibitors, beta-blockers, and spironolactone) alone or in combination with cardiac-resynchronization therapy with either a pacemaker or a pacemaker-defibrillator. The primary composite end point was the time to death from or hospitalization for any cause. RESULTS: As compared with optimal pharmacologic therapy alone, cardiac-resynchronization therapy with a pacemaker decreased the risk of the primary end point (hazard ratio, 0.81; P=0.014), as did cardiac-resynchronization therapy with a pacemaker-defibrillator (hazard ratio, 0.80; P=0.01). The risk of the combined end point of death from or hospitalization for heart failure was reduced by 34 percent in the pacemaker group (P<0.002) and by 40 percent in the pacemaker-defibrillator group (P<0.001 for the comparison with the pharmacologic-therapy group). A pacemaker reduced the risk of the secondary end point of death from any cause by 24 percent (P=0.059), and a pacemaker-defibrillator reduced the risk by 36 percent (P=0.003). CONCLUSIONS: In patients with advanced heart failure and a prolonged QRS interval, cardiac-resynchronization therapy decreases the combined risk of death from any cause or first hospitalization and, when combined with an implantable defibrillator, significantly reduces mortality.

  1. Guidelines for the Early Management of Patients With Acute Ischemic Stroke2013
  2. The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure2005
  3. Treatment of Comatose Survivors of Out-of-Hospital Cardiac Arrest with Induced Hypothermia2002
  4. Mild Therapeutic Hypothermia to Improve the Neurologic Outcome after Cardiac Arrest2002
  5. Bystander intervention in emergencies: Diffusion of responsibility.1968

Metadata from OpenAlex (CC0). Citations are generated from the published record.